

Biot Korea Inc.

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Biot Korea Inc.
○ Representative	Yeongjun Chang
○ Establishment year	2017
○ Specialized Field	Medical robot
○ Address	302, 43-26, Cheomdangwagi-ro 208beon-gil, Buk-gu, Gwangju, Republic of Korea
○ Home page	- Homepage: www.biotinc.com
○ Enterprise Brief Introduction	BIOT is a young start-up researching medical robot systems such as RAPIDS Platform, an automated molecular diagnosis system, and Stem Cell Navigator, a medical device platform that enables physical delivery of therapeutic agents. We are commercializing our products with many domestic and foreign researchers and top hospitals for a healthy future for humanity.
○ Product and Pipeline Introduction	<p>1. The world's first medical robot capable of collecting non-face-to-face samples of respiratory viral infections "RAPIDS Platform"</p> <p>- Introduction: The RAPIDS Platform, which makes it possible to collect samples performed face-to-face by medical staff on a non-face-to-face basis, through remote control, can dramatically prevent secondary infections by medical staff that can occur when sampling high-risk respiratory viruses It can solve many different problems such as fatigue and environmental problems.</p> <p>2. "Stem Cell Navigator"</p> <p>- Introduction: It is a medical device that can maximize the therapeutic effect of diseases by administering micro-sized structures including cell therapy products and capable of loading medicines in a minimally invasive manner, and moving them to target areas in the body using an electromagnetic external drive device.</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>[Patent]</p> <p>-registration in Korea : 3 -application in Korea : 9 -overseas application : 8</p> <p>[Thesis]</p> <p>- Characterization and Synthesis of Additivecoated BaTiO₃ Nano-powder and others -Human adipose-derived mesenchymal stem cell-based medical microrobot system for knee cartilage regeneration In vivo. (IF: 19.4) and 25 domestic and foreign films. -Liposomal angiogenic peptides for ischemic limb perfusion: comparative study between different administration methods. (IF: 6.4) and 27 domestic and foreign films.</p>